12 recruiting, 8 active not recruiting, 3 not yet recruiting, 2 unknown. 26 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Recruiting 12, Active not recruiting 8, Not yet recruiting 3, Unknown 2, Completed 1 |
| Phase 2 | 11 | Recruiting 7, Active not recruiting 2, Completed 1, Not yet recruiting 1 |
Follow Large B-cell Lymphoma: new trials by email Literature Review of Large B-cell Lymphoma trials Research Report on Large B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas Golcadomide, Pemetrexed, Rituximab - Large B-cell Lymphoma, Central Nervous System Lymphoma | Phase 1 | Not yet recruiting | Allison Winter | 18 | 2026-10-01 | 2026-08-21 |
| Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL Polatuzumab Vedotin, Rituximab, Cyclophosphamide - Large B-cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 40 | 2026-06-15 | 2026-06-30 |
| NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma NT-I7, CAR T-cell therapy - Large B-cell Lymphoma | Phase 1 | Recruiting | Washington University School of Medicine | 24 | 2026-03-12 | 2026-09-29 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies UB-VV400, Rapamycin - Large B-cell Lymphoma | Phase 1 | Recruiting | Nanjing IASO Biotechnology Co., Ltd. | 70 | 2025-04-11 | 2025-09-18 |
| A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies Surovatamig, Prednisone (or equivalent), Rituximab - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 408 | 2025-01-30 | 2026-10-28 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases JWCAR201 - B-cell Tumors, Autoimmune Diseases | Phase 1 | Not yet recruiting | RenJi Hospital | 15 | 2024-09-01 | 2024-08-22 |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) EB103 - B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins | Phase 1 / Phase 2 | Recruiting | Estrella Immunopharma, Inc. | 27 | 2024-06-01 | 2026-10-01 |
| Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) SC262 - Non Hodgkin's Lymphoma, Large B-cell Lymphoma | Phase 1 | Active not recruiting | Sana Biotechnology | 6 | 2024-04-18 | 2025-11-28 |
| AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas CD22CART Infusion - Follicular Lymphoma, Mantle Cell Lymphoma | Phase 1 | Recruiting | Stanford University | 148 | 2024-03-29 | 2026-08-12 |
| A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL GFH009, Zanubrutinib - Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 51 | 2024-03-20 | 2025-08-12 |
| Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies autologous hematopoietic stem cells added to planned CAR T - Hematologic Malignancy, Large B-cell Lymphoma | Phase 1 | Recruiting | Joshua Sasine, MD, PhD | 20 | 2024-03-02 | 2026-08-10 |
| A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies ALETA-001 - Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse | Phase 1 / Phase 2 | Recruiting | Cancer Research UK | 84 | 2024-02-07 | 2025-07-28 |
| CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms FCTX-CL19-1 (Tarcidomgen Kimleucel) - Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) | Phase 1 | Unknown | FamiCordTx | 6 | 2023-05-24 | 2024-09-19 |
| Axicabtagene Ciloleucel Reinfusion(Axi-Cel-2) in Relapsed/Refractory 2nd Line High-Risk NHL Axicabtagene Ciloleucel - Non-Hodgkin Lymphoma, Large B-cell Lymphoma | Phase 1 | Active not recruiting | Stanford University | 27 | 2023-05-23 | 2026-11-09 |
| Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide - Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Lyell Immunopharma, Inc. | 270 | 2023-05-09 | 2026-08-25 |
| Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies SYNCAR-001, STK-009, Cyclophosphamide - CLL/SLL, NHL | Phase 1 | Active not recruiting | Synthekine | 36 | 2023-04-23 | 2026-07-10 |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies CTX112 - B-cell Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 120 | 2023-03-10 | 2025-11-14 |
| Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma 19(T2)28z1xx TRAC T cell - B-Cell Lymphoma, Large B-cell Lymphoma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2023-02-23 | 2026-04-22 |
Showing 20 of 26. Sign in to see all of them.
Lymphoma, Mantle-Cell (11) · Lymphoma, Large B-Cell, Diffuse (10) · Lymphoma, Non-Hodgkin (10) · Lymphoma, Follicular (8) · Lymphoma, B-Cell (7) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma (5) · Lymphoma, B-Cell, Marginal Zone (5) · Recurrence (4) · Burkitt Lymphoma (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Waldenstrom Macroglobulinemia (3) · Dendritic Cell Sarcoma, Interdigitating (2) · Leukemia (2) · Autoimmune Diseases (1)
Hemic and Lymphatic Diseases (19) · Immune System Diseases (19) · Immunoproliferative Disorders (19) · Lymphatic Diseases (19) · Lymphoproliferative Disorders (19) · Neoplasms by Histologic Type (19) · Neoplasms (18) · Lymphoma (14) · Hematologic Diseases (9) · Lymphoma, B-Cell (9) · Lymphoma, Non-Hodgkin (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Disease Attributes (8) · Leukemia, Lymphoid (7)
Cyclophosphamide (5) · Rituximab (3) · fludarabine (3) · Doxorubicin (2) · Prednisone (2) · axicabtagene ciloleucel (2) · Busulfan (1) · Dexamethasone (1) · Gemcitabine (1) · Ice (1) · Immunotherapy, Adoptive (1) · Melphalan (1) · Pemetrexed (1) · Sirolimus (1) · Vincristine (1)
Stanford University (2) · Washington University School of Medicine (2) · Allison Winter (1) · AstraZeneca (1) · CRISPR Therapeutics AG (1) · Cancer Research UK (1) · Estrella Immunopharma, Inc. (1) · FamiCordTx (1) · Genfleet Therapeutics (Shanghai) Inc. (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Joshua Sasine, MD, PhD (1) · Lyell Immunopharma, Inc. (1) · Memorial Sloan Kettering Cancer Center (1) · Nanjing IASO Biotechnology Co., Ltd. (1) · Nkarta, Inc. (1)
United States (17) · China (7) · Australia (5) · France (2) · Germany (2) · Italy (2) · Japan (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · Austria (1) · Czechia (1) · Denmark (1) · Poland (1) · South Korea (1)
Allison M Winter, MD (1) · Chen-Lung Lin, MD (1) · David Russler-Germain, M.D., Ph.D. (1) · David Shook, MD (1) · Dehui Zou, Dr. (1) · Emilian Snarski (1) · Jae Park, MD (1) · John Gerecitano, MD, PhD (1) · Joshua Sasine, MD, PhD (1) · Keshu Zhou, MD (1) · Laura A Johnson, PhD (1) · Lei Fan (1) · Liangjing Lu (1) · Lugui Qiu, Ph.D (1) · Matthew Frank, MD, PhD (1)
PMID 38631712, PMID 41894687, PMID 41980020
R01CA286488 (1)